Diabetic kidney disease: act now or pay later

被引：4
作者：
Atkins, Robert C. [1 ]
Zimmet, Paul [2 ]
机构：
[1] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia
[2] Monash Univ, Dept Biochem & Mol Biol, Melbourne, Vic 3004, Australia
来源：
PEDIATRIC NEPHROLOGY | 2010年 / 25卷 / 02期
关键词：
RISK-FACTORS; TYPE-2; PREVALENCE; MICROALBUMINURIA; NEPHROPATHY; OUTCOMES; OBESITY;
D O I：
10.1007/s00467-009-1400-x
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：181 / 184
页数：4
相关论文
共 28 条
[1]   Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64) [J].
Adler, AI ;
Stevens, RJ ;
Manley, SE ;
Bilous, RW ;
Cull, CA ;
Holman, RR .
KIDNEY INTERNATIONAL, 2003, 63 (01) :225-232
[2]   Microvascular disease: what does the UKPDS tell us about diabetic nephropathy? [J].
Bilous, R. .
DIABETIC MEDICINE, 2008, 25 :25-29
[3]   Novel therapies of diabetic nephropathy [J].
Burney, Basil O. ;
Kalaitzidis, Rigas G. ;
Bakris, George L. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2009, 18 (02) :107-111
[4]   The rising prevalence of diabetes and impaired glucose tolerance - The Australian diabetes, obesity and lifestyle study [J].
Dunstan, DW ;
Zimmet, PZ ;
Welborn, TA ;
de Courten, MP ;
Cameron, AJ ;
Sicree, RA ;
Dwyer, T ;
Colagiuri, S ;
Jolley, D ;
Knuiman, M ;
Atkins, R ;
Shaw, JE .
DIABETES CARE, 2002, 25 (05) :829-834
[5]   Effect of a multifactorial intervention on mortality in type 2 diabetes [J].
Gaede, Peter ;
Lund-Andersen, Henrik ;
Parving, Hans-Henrik ;
Pedersen, Oluf .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (06) :580-591
[6]   10-year follow-up of intensive glucose control in type 2 diabetes [J].
Holman, Rury R. ;
Paul, Sanjoy K. ;
Bethel, M. Angelyn ;
Matthews, David R. ;
Neil, H. Andrew W. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1577-1589
[7]  
International Diabetes Federation and International Society of Nephrology, 2003, DIAB KIDN DIS TIM AC
[8]   Global burden of diabetes, 1995-2025 - Prevalence, numerical estimates, and projections [J].
King, H ;
Aubert, RE ;
Herman, WH .
DIABETES CARE, 1998, 21 (09) :1414-1431
[9]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[10]  
Lysaght MJ, 2002, J AM SOC NEPHROL, V13, pS37
123